I. Sklenar

502 total citations
23 papers, 375 citations indexed

About

I. Sklenar is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, I. Sklenar has authored 23 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Hematology. Recurrent topics in I. Sklenar's work include Cancer Treatment and Pharmacology (7 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). I. Sklenar is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). I. Sklenar collaborates with scholars based in Switzerland, United Kingdom and United States. I. Sklenar's co-authors include Peter Erb, Ş. Ş. Alkan, Terry C. Jones, Marco Bregni, Salvatore Siena, A. Johri, Ulrich Keller, José-Luis Dı́az, Terence J. Wilkin and A. M. Gianni and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Clinical Cancer Research.

In The Last Decade

I. Sklenar

21 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Sklenar Switzerland 13 132 94 92 59 49 23 375
S Sunaga Japan 4 57 0.4× 76 0.8× 96 1.0× 255 4.3× 34 0.7× 6 423
Giovanni Luca Pagliardi Italy 7 269 2.0× 72 0.8× 134 1.5× 122 2.1× 42 0.9× 12 507
Derek Sim United States 11 121 0.9× 30 0.3× 221 2.4× 66 1.1× 28 0.6× 25 432
Rebecca Patenia United States 14 154 1.2× 223 2.4× 37 0.4× 312 5.3× 41 0.8× 24 541
Anna Wolska Poland 13 166 1.3× 148 1.6× 75 0.8× 205 3.5× 13 0.3× 29 512
Agnieszka Chęcińska Netherlands 9 314 2.4× 182 1.9× 20 0.2× 107 1.8× 15 0.3× 10 477
Kristin Padavic United States 9 394 3.0× 205 2.2× 24 0.3× 178 3.0× 48 1.0× 10 612
Masafumi MURAI Japan 7 318 2.4× 71 0.8× 21 0.2× 52 0.9× 20 0.4× 19 430
Rosa Lovis United States 7 114 0.9× 74 0.8× 36 0.4× 208 3.5× 16 0.3× 9 408
Stefan A. Cohen United States 13 95 0.7× 152 1.6× 24 0.3× 209 3.5× 21 0.4× 21 420

Countries citing papers authored by I. Sklenar

Since Specialization
Citations

This map shows the geographic impact of I. Sklenar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Sklenar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Sklenar more than expected).

Fields of papers citing papers by I. Sklenar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Sklenar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Sklenar. The network helps show where I. Sklenar may publish in the future.

Co-authorship network of co-authors of I. Sklenar

This figure shows the co-authorship network connecting the top 25 collaborators of I. Sklenar. A scholar is included among the top collaborators of I. Sklenar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Sklenar. I. Sklenar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Østerlind, Kell, Juan Manuel Sepúlveda-Sánchez, Petr Zatloukal, et al.. (2005). Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7110–7110. 14 indexed citations
2.
Melichar, Bohuslav, Josep Tabernero, E. Casado, et al.. (2005). Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC). Journal of Clinical Oncology. 23(16_suppl). 3688–3688. 3 indexed citations
3.
Gore, Martin, S.B. Kaye, Amit M. Oza, et al.. (2005). Phase I trial of patupilone plus carboplatin in patients with advanced cancer. Journal of Clinical Oncology. 23(16_suppl). 5087–5087. 6 indexed citations
4.
Zuylen, Lia van, John Bridgewater, Alex Sparreboom, et al.. (2004). Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer. Clinical Cancer Research. 10(6). 1949–1955. 16 indexed citations
5.
Smit, Willem M., A.H. Honkoop, S. Špánik, et al.. (2004). A phase I/II dose-escalation trial of EPO906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer. Journal of Clinical Oncology. 22(14_suppl). 5102–5102. 2 indexed citations
6.
Belhadj, Karim, Hans D. Menssen, Wolfgang Kern, et al.. (2004). Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Clinical Cancer Research. 10(4). 1299–1305. 42 indexed citations
7.
Wolf, Hans‐Heinrich, Michael Borte, Mathieu Caulier, et al.. (2003). Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sanguinis. 84(1). 45–53. 37 indexed citations
8.
Siu, Lillian L., Eric K. Rowinsky, Lisa A. Hammond, et al.. (2002). A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.. PubMed. 8(7). 2157–66. 33 indexed citations
9.
Zuylen, Lia van, Alex Sparreboom, I. Sklenar, et al.. (2000). The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study. UCL Discovery (University College London).
10.
Brouwer, Rolf E., Koos Zwinderman, W. R. Bezwoda, et al.. (1999). Phase III efficacy study of interleukin‐3 after autologous bone marrow transplantation in patients with malignant lymphoma. British Journal of Haematology. 106(3). 730–736. 2 indexed citations
11.
Hofstra, L.S., Gunnar B. Kristensen, P.H.B. Willemse, et al.. (1998). Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.. Journal of Clinical Oncology. 16(10). 3335–3344. 5 indexed citations
12.
Kolbe, Karin, Christian Peschel, Daryl Despres, et al.. (1997). Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients. Bone Marrow Transplantation. 20(12). 1027–1032. 6 indexed citations
13.
Gianni, Alessandro M., Salvatore Siena, Marco Bregni, et al.. (1993). Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy. Annals of Oncology. 4(9). 759–766. 18 indexed citations
14.
Sklenar, I., Terence J. Wilkin, José-Luis Dı́az, Peter Erb, & Ulrich Keller. (1987). Spontaneous Hypoglycemia Associated With Autoimmunity Specific to Human Insulin. Diabetes Care. 10(2). 152–159. 35 indexed citations
15.
Sklenar, I., Terry C. Jones, Ş. Ş. Alkan, & Peter Erb. (1986). Association of Symptomatic Human Infection with Toxoplasma gondii with Imbalance of Monocytes and Antigen-Specific T Cell Subsets. The Journal of Infectious Diseases. 153(2). 315–324. 40 indexed citations
16.
17.
Kennedy, Marion, et al.. (1985). Evaluation of accessory cell heterogeneity. I. Differential accessory cell requirement for T helper cell activation and for T‐B cooperation. European Journal of Immunology. 15(1). 1–6. 12 indexed citations
18.
Sklenar, I., et al.. (1985). [Antibody response to pneumococcal polysaccharide antigens following splenectomy and replantation of autologous splenic tissue].. PubMed. 30. 107–12. 1 indexed citations
19.
Sklenar, I., et al.. (1982). Association of specific immune response to pork and beef insulin with certain HLA-DR antigens in type 1 diabetes.. BMJ. 285(6353). 1451–1453. 7 indexed citations
20.
Sklenar, I., P Spring, & L Dettli. (1977). One-dose and multiple-dose kinetics of minocycline in patients with renal disease. Inflammation Research. 7(3). 369–377. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S Sunaga Breakdown of academic impact, for papers by Giovanni Luca Pagliardi Breakdown of academic impact, for papers by Derek Sim Breakdown of academic impact, for papers by Rebecca Patenia Breakdown of academic impact, for papers by Anna Wolska Breakdown of academic impact, for papers by Agnieszka Chęcińska Breakdown of academic impact, for papers by Kristin Padavic Breakdown of academic impact, for papers by Masafumi MURAI Breakdown of academic impact, for papers by Rosa Lovis Breakdown of academic impact, for papers by Stefan A. Cohen
Rankless by CCL
2026